Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder due t o antiplatelet autoantibodies, many of which are directed against platelet membrane glycoprotein (GP) Ilb-llla or GPlb-IX. In a recent study, we described plasma autoantibodies from 13 selected ITP patients, which required the presence of the putative GPllla cytoplasmic region for antibody binding. Since this region may not be available for antibody binding under physiologic conditions, we evaluated the frequency of binding t o this or other regions of GPllb-llla by platelet-associated and plasma autoantibody from a group of chronic ITP patients. We studied platelet-associated autoantibodies in 27 patients and plasma antibodies in 21 patients; in 15 patients, both were studied. To determine if autoantibodies were directed t o the cytoplasmic portion of GPllla or t o another portion of the GPllb-llla molecule, antibody eluted from patient platelets or plasma antibody was tested in an antigen capture assay for binding t o GPllb-llla obtained from Chinese hamster ovary (CHO) HRONIC IMMUNE thrombocytopenic purpura (ITP)
Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder due t o antiplatelet autoantibodies, many of which are directed against platelet membrane glycoprotein (GP) Ilb-llla or GPlb-IX. In a recent study, we described plasma autoantibodies from 13 selected ITP patients, which required the presence of the putative GPllla cytoplasmic region for antibody binding. Since this region may not be available for antibody binding under physiologic conditions, we evaluated the frequency of binding t o this or other regions of GPllb-llla by platelet-associated and plasma autoantibody from a group of chronic ITP patients. We studied platelet-associated autoantibodies in 27 patients and plasma antibodies in 21 patients; in 15 patients, both were studied. To determine if autoantibodies were directed t o the cytoplasmic portion of GPllla or t o another portion of the GPllb-llla molecule, antibody eluted from patient platelets or plasma antibody was tested in an antigen capture assay for binding t o GPllb-llla obtained from Chinese hamster ovary (CHO) HRONIC IMMUNE thrombocytopenic purpura (ITP) C is an autoimmune disorder caused by antiplatelet autoantibodies.'.' Many of these autoantibodies are directed against epitopes on platelet membrane glycoprotein (GP) complexes, particularly GPIIb-IIIa and GPIb/IX3-' and some are known to bind to GPIIIa.' In a recent study, we evaluated the binding of plasma antibodies from a selected group of chronic ITP patients to synthetic peptides corresponding to different regions of GPIIIa.8 Of 13 chronic ITP patients, whose plasma antibodies bound to solubilized GPIIb-IIIa, five had plasma antibody that bound to two GPIIIa peptides, which together comprise the carboxy terminal region of GPIIIa. Furthermore, the plasma from 10 of these 13 patients, including those reactive with the two peptides, required the presence of the GPIIIa carboxy terminus for antibody binding. This was demonstrated by the lack of autoantibody binding to recombinant GPIIIa lacking amino acids 728 to 762.
Since the carboxy terminus of GPIIIa may not be available for antibody binding in intact platelets under physiologic conditions, it is important to compare the specificity of the platelet-associated antibody from these patients with that of the plasma antibody. In the present study, we find that plasma anti-GPIIb-IIIa in these patients is directed predominantly toward the carboxy terminus of GPIIIa, while antibody eluted from the patient's platelets binds to sites located elsewhere. This provides direct evidence that plasma anti-GPIIb-IIIa autoantibodies in chronic ITP are not always the unbound "leftover" antibody of identical platelet-bound antibody and that, in certain patients, there are at least two distinct regions of GPIIb-IIIa recognized by antiplatelet autoantibodies.
MATERIALS AND METHODS

Patients
Thirty-two patients with chronic ITP, three patients with posttransfusion purpura (PTP) due to anti-PIA' alloantibody, and seven cells transfected with GPllb and either intact GPllla or GPllla lacking the carboxy terminal 35 residues. Of the 21 plasma autoantibodies tested, 13 bound primarily t o the carboxy terminus of GPllla and eight t o other epitopes. Conversely, all 26 platelet-associated autoantibodies, including eight of the 13 with anti-carboxy terminus antibodies, bound t o epitopes in other regions of GPllb-llla. Comparison of the degree of antibody adsorption by intact or lysed platelets indicated that epitopes on the c-terminal region of GPllla are relatively inaccessible on the surface of intact washed platelets when compared with other epitopes. We conclude that the importance of plasma autoantibodies in chronic ITP patients should be interpreted cautiously, since their specificity may differ from that of antibodies bound t o the platelet. Whether antibodies against the c-terminus of GPllla are of pathogenetic importance remains t o be determined, although patients with these antibodies have particularly severe disease. @ 1992 by The American Society of Hematology.
normal subjects were studied. Chronic ITP patients had isolated thrombocytopenia, normal or increased numbers of megakaryocytes in the bone marrow, and no evidence of other types of immune thrombocytopenia. Of the chronic ITP patients, all 30 patients tested had demonstrable platelet-associated antibodies against platelet GPIIb-IIIa detected using a previously described assay; platelets were not available for study in two patients. Citrated plasma was studied in all 32 patients, using the same assay, and 27 had detectable plasma anti-GPIIb-IIIa antibodies.
Monoclonal Antibodies
The following murine monoclonal antibodies were used: 2A9 (anti-GPIIb, IgG,) and 3F5 (anti-GPIIb-IIIa complex, IgG,) provided by Dr VL Woods, University of California, San Diego, and HB-43 (anti-human IgG, heavy chain, IgG,) obtained from American Type Culture Collection, Rockville, MD. The antibodies were purified from ascites using the Monoclonal Antibody Purification System (Biorad, Richmond, CA). Radioiodination of HB-43 was accomplished using the iodogen method and 3F5 was biotinylated using 150 Fg N-hydroxy succinimide-biotin/ 1 mg antibody.
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Platelet Preparation
Platelets from patients and normal subjects were obtained by differential centrifugation of EDTA-anticoagulated blood; after six washes with isotonic citrate buffer, pH 6.2, the washed platelets were resuspended to the desired concentration in citrate buffer. Platelet lysate was prepared by solubilization in 1% Triton X-100 for 30 minutes at 4°C. Insoluble material was removed by ultracentrifugation.
Elution of Platelet-Associated Antibody
Washed platelets (1 to 10 x 10') were lysed by freezing and thawing twice (to expose the cytoplasmic domains of GPIIb and GPIIIa) and then resuspended in 1 mL of 0.1 mol/L glycine-HC1, pH 2.5. After incubation for 15 minutes at room temperature and centrifugation for 30 minutes at 100,00Og, the supernatant was removed and immediately neutralized with 1 mol/L Tris-HC1, pH 9.0. After dialysis against phosphate-buffered saline (PBS), antibody eluates were stored at -20°C.
Purification of Plasma Anti-GPIIb-IIIa Antibody
In some patients, who had either low-titer plasma antibody and/or high background activity in the assays, it was necessary to prepare affinity-purified antibody. Purified GPIIb-IIIa (20 mg), prepared as previously described: was coupled to 1 g of CNBrSepharose 4B (Pharmacia, Uppsala, Sweden) according to manufacturer's instructions. Heat-inactivated plasma (6 mL) from chronic ITP, PTP, or normal donors was added to the GPIIb-IIIaSepharose and incubated for 4 hours at room temperature or overnight at 4°C. After washing extensively with PBS, bound antibody was eluted with 0.1 mol/L glycine-HC1, pH 2.5, and then immediately neutralized with 1 mol/L Tris-HC1, pH 9.0.
Evaluation of Antigenic Location Using Recombinant GPIIIIIIa
Transfection of Chinese hamster ovary cells with human platelet GPZZb-ZZZa. The procedure for preparing Chinese hamster ovary (CHO) cell recombinants is described in detail elsewhere! Briefly, full-length cDNAs for GPIIb, GPIIIa, and GPIIIa lacking nucleotides coding for the carboxy terminal amino acids 728 to 762 were subcloned into the eukaryotic vector CDM8 and used to transfect CHO cells as described?" The stable clonal line expressing intact GPIIb-IIIa is designated A5. The CHO cell line transfected with GPIIb and the truncated GPIIIa lacking the 35 carboxy terminal amino acids is designated ET1 in this study, although the official designation is 11, f3, A728. Full characterization of these cell lines has been published: Untransfected cells served as controls. The CHO cells were washed three times with 3.5 mmol/L EDTA-PBS and once with PBS. After resuspension (107/mL) in PBS, the cells were solubilized by incubation in 1% Triton X-100 containing 0.4 mmol/L phenylmethylsufoniumfluoride (PMSF) for 30 minutes at 4°C. Insoluble material was removed by ultracentrifugation for 30 minutes at 100,000g.
All assays were performed in triplicate. Microtiter wells were coated overnight at 4°C with 100 FL of anti-GPIIb (2A9 10 Fg/mL in 0.1 mol/L NaHCO,). After six washes with 0.05% Tween-20 in PBS (wash buffer), any remaining binding sites were blocked by adding 200 pL of 2% bovine serum albumin (BSA)-PBSTween to each well and incubating for 60 minutes at room temperature. After six washes, 100 pL of the following CHO cell lysates were added to different wells: A5 (intact GPIIb-IIIa), ET1 (GPIIb with GPIIIa lacking the cytoplasmic domain), or untransfected CHO cells. After incubation for 60 minutes at room Assay. temperature and six washes, 100 p,L of eluted platelet-associated antibody or plasma antibody (1/10 plasma dilution or affinitypurified plasma antibody) was added and incubated for 60 minutes at room temperature. Following six washes, 100 FL of radiolabeled antihuman IgG (HB-43, 100,OOO cpm) was added and, after an additional 60-minute incubation and six washes, well-bound radioactivity was determined. Data are expressed as the net radioactivity after subtraction of cpm bound to the untransfected CHO cell control. All samples were assayed at least twice on separate dates.
Binding of eluates from control platelets or of control plasma to A5 or ET1 cells did not differ significantly from values obtained using untransfected CHO cells.
Antigen Availability on Intact and Lysed Platelets
Autoantibodies from some chronic ITP patients are directed primarily to antigens on the putative cytoplasmic portion of GPIIIa, while antibodies from other patients bind to different epitopes on the GPIIb-IIIa
To evaluate the availability of antigen on the cell surface to these various antibodies, plateletassociated or plasma antibodies from chronic ITP patients were preincubated, before assay, with either washed intact or lysed platelets to evaluate the degree of antibody adsorption.
Type 0 platelets were washed six times in citrate buffer containing 1 pg/mL PGE, and 2 pmol/L theophyllin to prevent activation, and then were divided into two aliquots, one of which was disrupted by freezing and thawing. Eluted platelet-associated antibody or plasma antibody, containing PGE, and theophyllin, was incubated with either intact or lysed platelets for 2 hours at room temperature, followed by centrifugation for 5 minutes at 3, OOOg and then for 30 minutes at 100,000g. The supematant fluid was removed and assayed.
Microtiter wells were coated with anti-GPIIb and blocked with 2% BSA as described above. Next, 100 p,L of normal platelet lysate (108/mL) was added to each well as an antigen source and incubated for 60 minutes at room temperature. After six washes, 100 pL of the following was added to separate wells: unadsorbed platelet-associated or plasma antibody; platelet-associated or plasma antibody adsorbed with intact platelets; or platelet-associated or plasma antibody adsorbed with lysed platelets. After a 60-minute incubation at room temperature and six washes, well-bound antibody was detected with labeled anti-human IgG as described above. Results were expressed as % inhibition = 100 -(cpm adsorbed antibody/cpm unadsorbed antibody X 100).
Quantitative antibody adsorption.
Assay.
Demonstration of Plasma Anti-GPIIb-IIZa Autoantibody Binding to Autoantigen
Microtiter wells coated with anti-GPIIb and blocked with BSA were incubated for 60 minutes with 100 p,L of either isologous or autologous platelet lysate (108/mL) as an antigen source. After six washes, diluted autologous plasma or affinity-purified autologous plasma antibody was added and incubated for 60 minutes. Following six washes, well-bound antibody was detected using labeled anti-human IgG.
RESULTS
Antibody Binding to Recombinant GPIIb-IIIa
Preliminary studies showed that microtiter wells coated with anti-GPIIb (2A9) bound similar amounts of recombinant GPIIb-IIIa obtained from either A5 or ET1 CHO cell recombinants. This was demonstrated by incubating saturating amounts of anti-Pl*' alloantibody, whose antigenic site is known to be located on the extracellular amino terminal
GPIIb-IIIa anchored to 2A9. As previously reported, similar binding to both recombinant forms of GPIIb-IIIa was seen! In addition, similar binding of biotinylated murine complex-specific anti-GPIIb-IIIa antibody (3F5) to the two recombinants was noted (data not shown).
In 21 of the 32 chronic ITP patients, the binding of plasma antibody to recombinant GPIIb-IIIa could be studied (Table 1, ITP-1 to -21 ). In 13 of these patients (ITP-1 to -13), greater than 75% of the plasma antibody binding was dependent on the presence of the carboxy terminal region of GPIIIa as demonstrated by the lack of binding to GPIIb-IIIa from ET1 cells when compared with binding to A5 GPIIb-IIIa. In the remaining eight patients, plasma antibody bound in a similar manner to GPIIb-IIIa from both A5 and ET1 cells, showing that the major antigenic sites in these patients were located in another region of GPIIb-IIIa. These results indicate that the c-terminal region is an important antigenic stimulus for
Plasma antibody.
the production of plasma autoantibodies in some chronic ITP patients.
In eight of the 13 patients with antibodies primarily to the carboxy terminus of GPIIIa (Fig 1 and Table 1, ITP-1 to -8) , platelet-associated antibodies were also analyzed; platelet samples were unavailable in four patients and antibody eluate was nonreactive in another. In every case, the binding of platelet-associated autoantibodies from these eight patients did not depend on the carboxy terminus of GPIIIa, as shown by the similar binding of antibody to GPIIb-IIIa derived from A5 and ET1 cells. Furthermore, of the 27 platelet-associated autoantibodies studied (Table 1 , ITP-1 to -8 and ITP-14 to -32), none required the presence of the c-terminal region of GPIIIa for antibody binding. This shows that antibody against the c-terminal region of GPIIIa did not represent a significant portion of platelet-bound antibody in any of the patients tested, despite its predominance in the plasma in patients ITP-1 to -8.
Platelet-associated autoantibody. 
Accessibility of the GPIIIa Carboy Terminus in Intact and Lysed Platelets
Serially diluted intact or lysed washed platelets were preincubated with plasma antibody against the c-terminal region (ITP-1, -2, and -ll), platelet-associated antibody (ITP-2 and -19), or anti-PIA' alloantibody (PTP-1); residual antibody activity was then assayed. Representative studies are shown in Figs 2 and 3. From these curves, the number of platelets (intact or lysed) required to adsorb 50% of antibody activity was calculated. As shown in Table 2 , it took 26 to 28 times more intact than lysed platelets to adsorb an equal amount of autoantibody from plasma containing antibody primarily against the c-terminal region of GPIIIa (amino acids 728 to 762), while plateletassociated autoantibody required only 1.8 to 2.2 times as many intact platelets. Anti-PlA1 alloantibody was absorbed equally well by intact and disrupted platelets. These data show that epitopes on the c-terminal region of GPIIIa are relatively inaccessible on the surface of intact washed platelets (3.6% to 4.3% relative to lysed platelets or approximately 1,800 to 2,150 molecules per platelet assuming 50,000 molecules of GPIIb-IIIa per intact platelet).
Confirmation That Plasma Antibodies to the c-Terminus of GPIIIa Are True Autoantibodies
It is possible that, in some chronic ITP patients, plasma antibodies against the c-terminus of GPIIIa may be alloantibodies due to transfusion or pregnancy. In patients ITP-1 and ITP-9, this is not possible, since they had been neither transfused nor pregnant. In patients ITP-2, -3, -5, -8, -9 , and -22, plasma antibody was tested for the ability to bind to autologous GPIIb-IIIa. As shown in Table 3 , each of these plasmas showed significant binding to both autologous and isologous GPIIb-IIIa, confirming that these were autoantibodies.
DISCUSSION
Antiplatelet autoantibodies in chronic ITP are often specific for platelet membrane GPIIb-IIIa?-' a calciumdependent heterodimer that serves as the platelet fibrinogen receptor. Of these, a portion react with GPIIIa.' Despite the identification of anti-GPIIb-IIIa autoantibodies by several investigators, little is known about their precise antigenic specificity. Recently, we have shown that some plasma anti-GPIIb-IIIa autoantibodies recognize epitopes on the carboxy terminus of GPIIIa. nant GPIIb-IIIa, while little or no binding was seen using recombinant GPIIb-IIIa lacking the c-terminal region (amino acids 728 to 762). It was not known if these antibodies against the c-terminus of GPIIIa were bound to circulating platelets. In the present study, the binding pattern of acid-eluted platelet-associated autoantibody was compared with that of plasma antibody. Of the 32 patients studied, 13 had plasma autoantibody to the GPIIIa carboxy terminus, as shown by the marked reduction of binding to recombinant GPIIb-IIIa lacking the c-terminus of GPIIIa.
Plasma antibody against another region of GPIIb-IIIa was noted in eight patients, and no plasma antibody was detected in the remaining 12 patients. When plateletassociated autoantibody was studied, similar binding to both forms of recombinant GPIIb-IIIa was noted in each of the 26 patients where data were evaluable. Most signifi- Anti-other *Washed intact or lysed platelets were preincubated with antibody (plasma or platelet eluate) for 2 hours at room temperature. After centrifugation, the supernatant fluid was assayed for residual antibody. The number of platelets to adsorb 50% of the antibody was calculated.
tAnti-GPllla carboxy terminus, autoantibody to the c-terminal portion of GPllla (amino acids 728 to 762); anti-other, autoantibody to other regions of GPllb-Ma; anti-Pl"', alloantibody to the amino terminal region of GPllla.
SI/L ratio, number of intact platelets/number of lysed platelets required for 50% antibody adsorption. cantly, in eight of these patients, the plasma antibody was dependent on the presence of the c-terminus of GPIIIa, whereas the platelet-associated antibody from the same patient was not. Thus, these data unambiguously demonstrate that in a single patient, autoantibodies against GPIIIa may react with multiple regions of the protein. This suggests that the immune response is antigen-driven and not the result of molecular mimicry.
Two possible explanations for the disparity between the plasma and platelet-associated antibodies' dependence on the c-terminus of GPIIIa are (1) the anti-c-terminus antibody is either not eluted from the patients' platelets or destroyed by the elution conditions, although this is unlikely since plasma antibody to the GPIIIa c-terminus binds to and can be eluted from both washed platelets and purified GPIIb/IIIa using the same conditions; and (2) the c-terminus of GPIIIa is inaccessible, ie, cytoplasmic, and the patient forms autoantibodies against these inaccessible epitopes when they are exposed as a result of platelet destruction by the primary antibody. The high concentration of these antibodies in the plasma may result from their relative lack of adsorption by the inaccessible epitopes on platelets or megakaryocytes.
We favor the second possibility, because the arrangement of hydrophobic sequences in GPIIIa" predicts a signal peptide and a single transmembrane domain. The charge distribution about the second hydrophobic region strongly favors an N-terminus out topography." Furthermore, qualitative immunofluorescence studies using antibodies against the c-terminus of the related chicken B1-integrin subunit show that this region is largely inaccessible in intact cells,14 although it should be noted that other data suggest that a fraction of the B1-integrin may not be transmembrane.'' In the present study, using a quantitative immunoabsorption technique, we demonstrated that less than 5% of the c-terminus antigenic sites were available on intact platelets. However, it should be noted that some antigenic sites were expressed on washed intact platelets (estimate from 1,800 to 2,150 molecules per platelet) and conceivably enough to result in platelet destruction if a similar number were expressed in vivo, since it has been estimated that approxi-
